Inogen, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$348Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
4,957clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Inogen One G5 Oxygen Concentrator - Bluetooth $76K associated (2023-2025)
- Inogen Rove 6 $72K associated (2023-2025)
- Inogen $34K associated (2023-2025)
- Yuwell Sleep Apnea Breathing Therapy Mask $10K associated (2023-2025)
- Simeox 200 $9,900 associated (2023-2025)
- Inogen At Home Stationary Concentrator $6,560 associated (2023-2025)
- Inogen One G3 Oxygen Concentrator $1,131 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Heather Giannini | Marlton, NJ | Pulmonary Disease | $18,885.15 |
| Ayodeji Adegunsoye | Chicago, IL | Pulmonary Disease | $12,323.50 |
| Joao Deandrade | Nashville, TN | Pulmonary Disease | $12,278.64 |
| Wassim Labaki | Ann Arbor, MI | Pulmonary Disease | $11,022.06 |
| Alejandra Lastra | Chicago, IL | Pulmonary Disease | $10,375.00 |
| Jerry Krishnan | Chicago, IL | Pulmonary Disease | $9,721.02 |
| Neil Macintyre | Durham, NC | Critical Care Medicine (Internal Medicine) | $9,500.00 |
| Richard Casaburi | Torrance, CA | Pulmonary Disease | $8,246.51 |
| Frederic Seifer | Potsdam, NY | Pulmonary Disease | $6,916.73 |
| Colin Swenson | Atlanta, GA | Pulmonary Disease | $5,819.81 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.